Jubilant Ingrevia Ltd

- No explicit mention of any current or upcoming fundraising through debt or equity in the transcript. - Capital expenditure during the quarter was Rs.116 crore, primarily funded through internal accruals. - The company’s net debt as of June 30, 2024, was Rs.677 crore with a net debt-to-equity ratio of 1.5x based on trailing 12-month EBITDA. - No indication from management about plans for incremental debt or equity raising. - Focus appears to be on internal funding for expansion and ongoing initiatives.

- Commissioned an agrochemical plant in January 2024 capable of producing both intermediates and active ingredients; currently under evaluation. - Plans to undertake modifications and incremental CAPEX in the agrochemical plant to meet demand. - Significant investment has already been made in the new agrochemical plant. - Expansion plans for fine chemicals with multipurpose plants at Gajraula and Bharuch facilities expected to serve growth for the next five years. - Ongoing CAPEX of Rs. 116 crore in Q1 FY25 funded primarily through internal accruals. - Multiple initiatives under "Pinnacle 345" growth roadmap, including investments in high potential product categories and sustainability efforts such as sourcing renewable energy. - CDMO business expected to grow with steady investments, targeting 25%-30% year-on-year growth; includes pharma, agro, and semiconductor opportunities.

- Jubilant Ingrevia aims to grow revenue 3x from FY24 to FY29, targeting Rs. 12,000 to Rs. 13,000 crore+ revenue. - Specialty Chemicals business expected to grow steadily with 23%-25% EBITDA margin aspirational target. - CDMO business (Pharma and Agro) to grow at least 20%-25% annually, with several advanced-stage opportunities to convert. - Agrochemical demand and volumes expected to recover gradually with easing inventory destocking; growth moderated but steady. - Nutrition business volumes increased ~14%-15% QoQ, with future improvement hinging on new food/cosmetic grade products launching in Q3 FY25. - New product lines (diketene, food-grade choline bitartrate) showing strong traction and contributing to volume growth. - Overall specialty segments reported stable or increasing volumes seasonally, with expectations of volume growth in FY25 compared to FY24. - Continued focus on customer centricity and ramping up new plants to sustain growth momentum.

- Jubilant Ingrevia aspires to grow revenue from a steady state of ~Rs. 4,500 crore to Rs. 12,000-13,000 crore in five years (Pinnacle 345 vision). - Target EBITDA margin is 20%+ at the overall company level, with Specialty Chemicals expected to achieve 23%-25% EBITDA margins. - Nutrition segment margins are anticipated to improve to 17%-18%+ with the addition of specialty products and new plants. - The acetyl business is expected to sustain EBITDA margins around 10%-12%. - Specialty Chemicals business aims to sustain 20%+ EBITDA and potentially reach closer to 24%-25% as new products and CDMO opportunities scale up. - CDMO business is expected to grow at 20%-25% yearly, contributing significantly to profits. - Cost-saving initiatives are estimated to bring Rs. 120-140 crore annualized savings, enhancing profitability. - Overall, the company targets a 3x revenue and 4x EBITDA growth in five years from FY24 base, delivering strong earnings and EPS growth.

- The company is in the advanced stages of discussions with an agrochemical customer for a contract; the first objective is to sign the contract before finalizing servicing details. - The CDMO business is witnessing strong traction with new orders delivered during the quarter. - There are multiple projects in advanced discussions across Pharma, Agro, and Semiconductor sectors. - The Semiconductor-related CDMO opportunities have grown from 4-5 leads to 10-12 real leads, with samples already supplied to some customers. - Growth aspiration for CDMO business is steady at 20%-25% CAGR, with a potential jump based on lumpier agrochemical projects. - Overall, the company is building a robust CDMO opportunity pipeline for the coming years, although timing of revenue realization is uncertain due to the nature of the business. - Expansion plans for the next 5 years can be accommodated within the existing Gajraula and Bharuch facilities.